


Gp 1642



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

July 21, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

PATENT
Attorney Docket No.: 17634-000513US
Client Reference No.: E-142-96

4
KD

7-31-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brian R. Murphy et al.

Application No.: 09/444,221

Filed: November 19, 1999

For: PRODUCTION OF ATTENUATED
RESPIRATORY SYNCYTIAL VIRUS
VACCINES FROM CLONED
NUCLEOTIDE SEQUENCES

Examiner: Unassigned

Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

RECEIVED

JUL 31 2000

TECH CENTER 1600/2300

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 08/892,403, filed July 15, 1997 (Attorney Docket No. 17634-000510US), unless otherwise indicated. Applicants respectfully request that the cited information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

It is further requested that the disclosure and claims presently or subsequently presented in the following, copending U.S. Patent Applications, as well as any related applications now or subsequently claiming priority to one or more of the following U.S. Patent

Not over
8-14-01
9-20-01

Applications, be expressly considered and made of record in the instant case as potentially disclosing or claiming subject matter material to examination of the present application.

U.S. Patent Application No. 08/039,945, filed on 04/09/93, by Murphy et al.;

U.S. Patent Application No. 08/453,304, filed on 05/30/95, by Murphy et al.;

U.S. Patent Application No. 08/720,132, filed on 09/27/96, by Collins, Peter;

U.S. Patent No. 5,882,651, issued on 03/16/99, to Murphy. et al.;

U.S. Patent Application No. 09/291,894, filed on 04/13/99, by Collins, et al.;

U.S. Provisional Patent Application No. 60/129,006, filed on 04/13/99, by
Murphy et al.;

U.S. Patent No. 5,922,326, issued on 07/13/99, to Murphy, Brian.;

U.S. Patent Application No. 09/444,067, filed on 11/19/99, by Murphy et al.;

U.S. Patent No. 5,993,824, issued on 11/30/99, to Murphy et al.;

U.S. Provisional Patent Application No. 60/213,708, filed on 06/23/00, by
Kremple et al.;

U.S. Patent Application No. 09/602,212, filed on 06/23/00, by Buchholz et al.;

U.S. Patent Application No. 09/611,829, filed on 07/07/00, by Collins, Peter;

U.S. Patent Application for PRODUCTION OF RECOMBINANT
RESPIRATORY SYNCYTIAL VIRUSES EXPRESSING IMMUNE MODULATORY
MOLECULES, filed by Collins, Peter on 07/12/00, and identified by Attorney Docket No.
015280-388100US (claiming priority to U.S. Provisional Patent Application No. 60/143,425,
filed on 07/13/99).

Applicants believe that their invention as claimed is patentable over the above references taken alone or in any combination. As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information. No inference should be drawn as to the pertinence of the references based on the order in which they are presented.


Brian R. Murphy, Peter L. Collins, Stephen S.
Whitehead, Alexander A. Bukreyev, Katalin
Juhasz, Michael N. Teng
Application No.:
Page 3

PATENT

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Dated: 7/21/00


Jeffrey J. King
Reg. No. 38,515

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 206-467-9600
Fax: 415-576-0300

JJK:imp

SE 5002495 v2

RECEIVED
JUL 31 2000
TECH CENTER 1600/2999